AYTU Stock Analysis: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$2.68
0.04 (1.52%)
▲
5d:
+0.75%
30d:
+2.88%
90d:
+3.08%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AYTU shows positive signals but monitor for confirmation. Market pricing in 1.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: AYTU shows positive signals but monitor for confirmation. Market pricing in 1.8% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $2.68, which is considered slightly high relative to its 30-day fair value range of $2.52 to $2.68. The stock's valuation (Forward PE: 15.8) is in line with its historical norms (14.9). At these levels, the market is pricing in 1.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is in a uptrend. Immediate support is located at $2.50, while resistance sits at $2.80.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.67 (+260.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AYTU is in a uptrend. Immediate support is located at $2.50, while resistance sits at $2.80.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.67 (+260.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$2.52 -
$2.68
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 260.7% below Wall St target ($9.67)
- NEUTRAL: Market pricing in 1.8% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$2.52 -
$2.68
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.50
Resistance Level
$2.80
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.76
Wall Street Target
$9.67
(+260.7%)
Revenue Growth (YoY)
-6.5%
Profit Margin
-39.0%
Valuation Premium vs History
+1.8% premium
PE vs Historical
15.8 vs 14.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.8%
(market-implied from PE analysis)
1-Year Target
$2.73
(+2%)
2-Year Target
$2.78
(+4%)
3-Year Target
$2.83
(+6%)
3-Yr Target (if PE normalizes)
(PE: 16→15)
PE COMPRESSION
$2.67
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: April 05, 2026 10:41 PM ET
Data refreshes hourly during market hours. Next update: 11:41 PM
Data refreshes hourly during market hours. Next update: 11:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 63 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 61 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 56 HOLD |
